Index -
P/E -
EPS (ttm) -27.33
Insider Own 31.52%
Shs Outstand 22.92M
Perf Week 5.48%
Market Cap 9.53B
Forward P/E 29.53
EPS next Y 11.51
Insider Trans -0.05%
Shs Float 19.17M
Perf Month -6.73%
Income -778.69M
PEG -
EPS next Q 2.87
Inst Own 68.44%
Short Float 2.55%
Perf Quarter 4.23%
Sales 2.58B
P/S 3.69
EPS this Y -12.69%
Inst Trans -7.85%
Short Ratio 1.71
Perf Half Y 20.66%
Book/sh 267.46
P/B 1.27
EPS next Y 11.93%
ROA -6.92%
Short Interest 0.49M
Perf Year 15.35%
Cash/sh 58.14
P/C 5.85
EPS next 5Y 12.00%
ROE -9.79%
52W Range 262.12 - 387.99
Perf YTD 5.30%
Dividend Est. -
P/FCF 38.65
EPS past 5Y -
ROI -8.82%
52W High -12.37%
Beta 0.90
Dividend TTM -
Quick Ratio 4.52
Sales past 5Y 3.42%
Gross Margin 54.41%
52W Low 29.72%
ATR (14) 11.01
Dividend Ex-Date -
Current Ratio 6.14
EPS Y/Y TTM -376.51%
Oper. Margin 13.35%
RSI (14) 50.89
Volatility 3.20% 3.46%
Employees 8030
Debt/Eq 0.19
Sales Y/Y TTM -5.15%
Profit Margin -30.18%
Recom 1.75
Target Price 399.33
Option/Short Yes / Yes
LT Debt/Eq 0.18
EPS Q/Q 541.90%
Payout -
Rel Volume 0.37
Prev Close 341.51
Sales Surprise 3.43%
EPS Surprise 73.70%
Sales Q/Q 2.79%
Earnings Oct 30 AMC
Avg Volume 284.92K
Price 340.01
SMA20 2.05%
SMA50 -0.42%
SMA200 7.07%
Trades
Volume 106,449
Change -0.44%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-01-24 Upgrade
Citigroup
Neutral → Buy
$350 → $400
Aug-28-24 Initiated
Wells Fargo
Equal Weight
$340
Jun-03-24 Resumed
Jefferies
Hold
$315
Apr-03-24 Downgrade
Citigroup
Buy → Neutral
$400 → $365
Dec-07-23 Initiated
UBS
Buy
$395
Jun-16-23 Initiated
Wells Fargo
Overweight
$550
Dec-07-22 Initiated
RBC Capital Mkts
Outperform
$565
Aug-25-22 Initiated
Credit Suisse
Outperform
$715
Jan-28-22 Reiterated
Citigroup
Buy
$915 → $750
Jan-08-20 Initiated
Wells Fargo
Overweight
$430
Jan-07-20 Initiated
Citigroup
Buy
$450
Oct-17-18 Initiated
Goldman
Buy
$350
Sep-20-18 Initiated
Morgan Stanley
Equal-Weight
$335
Feb-16-18 Downgrade
CL King
Buy → Neutral
Jul-13-17 Initiated
Wells Fargo
Outperform
Jun-28-17 Upgrade
Deutsche Bank
Hold → Buy
$220 → $255
Jan-18-17 Initiated
Deutsche Bank
Hold
$195
Oct-13-16 Initiated
CL King
Buy
May-06-15 Reiterated
Jefferies
Buy
$150 → $165
Dec-18-09 Initiated
Maxim Group
Buy
$125
Show Previous Ratings
Nov-24-24 08:05PM
Nov-21-24 09:00AM
Oct-31-24 11:52AM
(Morningstar Research) +8.35%
09:00AM
Oct-30-24 04:15PM
05:30PM
Loading…
Oct-14-24 05:30PM
Sep-23-24 07:45AM
Sep-22-24 06:00AM
Sep-19-24 04:20PM
Sep-09-24 10:56AM
Sep-06-24 06:43PM
Aug-28-24 05:25PM
Aug-22-24 04:30PM
Aug-20-24 08:30AM
Aug-01-24 04:15PM
04:30PM
Loading…
Jul-17-24 04:30PM
Jun-21-24 08:30AM
Jun-14-24 04:35AM
Jun-06-24 11:31AM
May-30-24 09:00AM
May-23-24 04:15PM
May-08-24 01:52PM
12:17PM
09:03AM
May-07-24 05:30PM
04:15PM
May-04-24 12:15AM
May-03-24 12:15PM
May-01-24 09:00AM
Apr-30-24 10:00AM
08:30AM
Loading…
Apr-26-24 08:30AM
Apr-18-24 10:03AM
09:00AM
Apr-16-24 10:56AM
Apr-11-24 05:30PM
Apr-10-24 04:15PM
Mar-31-24 04:34PM
Mar-20-24 08:30AM
Mar-12-24 08:27AM
Feb-24-24 03:25PM
Feb-22-24 04:30PM
Feb-15-24 04:15PM
Feb-05-24 11:32AM
Jan-24-24 05:00PM
Jan-02-24 04:15PM
Dec-12-23 12:42PM
Oct-27-23 11:21AM
Oct-26-23 04:15PM
Oct-05-23 08:30AM
Sep-19-23 05:43AM
Aug-28-23 04:15PM
Aug-03-23 04:15PM
Jul-26-23 04:15PM
Jul-20-23 04:30PM
Jul-10-23 04:30PM
09:00AM
Jun-26-23 04:00PM
Jun-21-23 08:00PM
Jun-01-23 08:00AM
May-08-23 08:00AM
May-04-23 04:15PM
Apr-26-23 08:00PM
Apr-12-23 04:11PM
Feb-17-23 09:00AM
Feb-16-23 04:05PM
Feb-08-23 08:00AM
Feb-07-23 09:00AM
Jan-06-23 09:00AM
Jan-04-23 09:00AM
Dec-07-22 02:30PM
07:51AM
Nov-30-22 09:25AM
Nov-20-22 03:48PM
Nov-08-22 01:50PM
Oct-31-22 08:30AM
Oct-28-22 01:01PM
Oct-27-22 05:45PM
04:05PM
Oct-26-22 11:31AM
Oct-18-22 12:01PM
Oct-17-22 08:30AM
Oct-13-22 09:08AM
Oct-12-22 01:10PM
Oct-11-22 04:09PM
(Investor's Business Daily)
07:53AM
Oct-10-22 11:00PM
06:25PM
(The Wall Street Journal)
04:48PM
(American City Business Journals)
02:24PM
Oct-03-22 10:00AM
Sep-01-22 10:59AM
10:45AM
Aug-29-22 11:45AM
Aug-25-22 12:20PM
Aug-22-22 12:56PM
Aug-18-22 08:32AM
Aug-15-22 09:09AM
Aug-04-22 03:01PM
Aug-03-22 04:15PM
Jul-29-22 11:28AM
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Last Andrew J. Officer Nov 06 '24 Proposed Sale 373.64 3,000 1,120,934 Nov 06 06:26 PM EVRAN SEDAT EVP, Global Supply Chain Oct 20 '24 Option Exercise 0.00 1,044 0 1,188 Oct 22 04:30 PM Last Andrew J. Officer Sep 12 '24 Proposed Sale 321.57 1,600 514,505 Sep 12 06:22 PM Last Andrew J. EVP, Chief Operating Officer Sep 06 '24 Option Exercise 299.24 3,000 897,720 10,559 Sep 10 02:05 PM Last Andrew J. EVP, Chief Operating Officer Sep 06 '24 Sale 329.94 3,000 989,815 7,559 Sep 10 02:05 PM Last Andrew J. Officer Sep 06 '24 Proposed Sale 329.94 3,000 989,815 Sep 06 04:16 PM Crowley Michael EVP, GBL Commercial Operations Sep 03 '24 Option Exercise 0.00 557 0 8,454 Sep 05 09:36 AM Crowley Michael EVP, GBL Commercial Operations Sep 02 '24 Option Exercise 0.00 434 0 8,052 Sep 05 09:36 AM Crowley Michael EVP, GBL Commercial Operations Sep 01 '24 Option Exercise 0.00 1,676 0 7,763 Sep 05 09:36 AM SCHWARTZ NORMAN D Chairman, President, and CEO Sep 03 '24 Option Exercise 0.00 2,320 0 439,479 Sep 04 08:35 PM SCHWARTZ NORMAN D Chairman, President, and CEO Sep 02 '24 Option Exercise 0.00 1,805 0 438,124 Sep 04 08:35 PM SCHWARTZ NORMAN D Chairman, President, and CEO Sep 01 '24 Option Exercise 0.00 6,352 0 436,864 Sep 04 08:35 PM COREY COLLEEN EVP, Global Human Resources Sep 03 '24 Option Exercise 0.00 495 0 18,656 Sep 04 08:25 PM COREY COLLEEN EVP, Global Human Resources Sep 02 '24 Option Exercise 0.00 361 0 18,290 Sep 04 08:25 PM COREY COLLEEN EVP, Global Human Resources Sep 01 '24 Option Exercise 0.00 1,100 0 18,020 Sep 04 08:25 PM BARRY JAMES EVP, President, LSG Sep 03 '24 Option Exercise 0.00 217 0 848 Sep 04 08:24 PM BARRY JAMES EVP, President, LSG Sep 02 '24 Option Exercise 0.00 265 0 726 Sep 04 08:24 PM BARRY JAMES EVP, President, LSG Sep 01 '24 Option Exercise 0.00 600 0 525 Sep 04 08:24 PM BARRY JAMES EVP, President, LSG Sep 04 '24 Sale 330.49 623 205,898 147 Sep 04 08:24 PM Last Andrew J. EVP, Chief Operating Officer Sep 02 '24 Option Exercise 0.00 903 0 8,017 Sep 04 08:19 PM Last Andrew J. EVP, Chief Operating Officer Sep 01 '24 Option Exercise 0.00 2,752 0 7,435 Sep 04 08:19 PM Allison Schwartz Director Sep 03 '24 Option Exercise 0.00 56 0 1,332 Sep 04 08:08 PM Allison Schwartz Director Sep 02 '24 Option Exercise 0.00 44 0 1,297 Sep 04 08:08 PM Allison Schwartz Director Sep 01 '24 Option Exercise 0.00 147 0 1,268 Sep 04 08:08 PM BARRY JAMES Officer Sep 04 '24 Proposed Sale 330.49 623 205,898 Sep 04 06:24 PM Alles Institute for Medical Re Director Aug 27 '24 Proposed Sale 311.34 990 308,225 Aug 27 12:45 PM Crowley Michael EVP, GBL Commercial Operations Jun 13 '24 Sale 281.91 369 104,023 6,573 Jun 14 01:42 PM Last Andrew J. EVP, Chief Operating Officer Apr 29 '24 Option Exercise 0.00 1,000 0 6,077 Apr 30 05:53 PM ERNST TIMOTHY S EVP, General Counsel & Sec Feb 28 '24 Option Exercise 326.15 2,500 815,375 5,897 Feb 29 05:24 PM ERNST TIMOTHY S EVP, General Counsel & Sec Feb 28 '24 Sale 330.55 2,500 826,375 3,397 Feb 29 05:24 PM Crowley Michael EVP, GBL Commercial Operations Feb 27 '24 Option Exercise 215.98 3,000 647,940 9,942 Feb 28 06:38 PM Crowley Michael EVP, GBL Commercial Operations Feb 27 '24 Sale 336.00 3,000 1,008,000 6,942 Feb 28 06:38 PM WRIGHT DARA EVP, President, CDG Dec 16 '23 Option Exercise 0.00 502 0 2,001 Dec 19 12:19 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite